Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 6 481-483, Copyright © 1992 by American Association for Cancer Research

ARTICLES

Allelic frequency of a p53 polymorphism in human lung cancer

A Weston, LS Perrin, K Forrester, RN Hoover, BF Trump, CC Harris and NE Caporaso
Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda 20892.

p53 is a tumor suppressor gene that is mutated in diverse tumor types. Here we report the frequencies of common polymorphic variants at codon 72 of the p53 gene in germline DNA of lung cancer cases and controls as determined by a polymerase chain reaction strategy. The observed allelic distribution was found to be significantly different between African-Americans and Caucasians in this U.S. population. The frequency of polymorphic variants was similar in lung cancer cases and controls after adjustment for race. However, among lung cancer patients the proline variant at codon 72 was in excess in adenocarcinoma patients by comparison with other histologies.

This article has been cited by other articles:

				L. E. Mechanic, E. D. Bowman, J. A. Welsh, M. A. Khan, N. Hagiwara, L. Enewold, P. G. Shields, L. Burdette, S. Chanock, and C. C. Harris Common Genetic Variation in TP53 Is Associated with Lung Cancer Risk and Prognosis in African Americans and Somatic Mutations in Lung Tumors Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 214 - 222. [Abstract] [Full Text] [PDF]

				N. Jain, V. Singh, S. Hedau, S. Kumar, M. K. Daga, R. Dewan, N. S. Murthy, S. A. Husain, and B. C. Das Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India Chest, December 1, 2005; 128(6): 3999 - 4007. [Abstract] [Full Text] [PDF]

				Y. Hu, M. P. McDermott, and S. A. Ahrendt The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2502 - 2509. [Abstract] [Full Text] [PDF]

				L. E. Mechanic, A. J. Marrogi, J. A. Welsh, E. D. Bowman, M. A. Khan, L. Enewold, Y.-L. Zheng, S. Chanock, P. G. Shields, and C. C. Harris Polymorphisms in XPD and TP53 and mutation in human lung cancer Carcinogenesis, March 1, 2005; 26(3): 597 - 604. [Abstract] [Full Text] [PDF]

				A. Matakidou, T. Eisen, and R.S. Houlston TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis Mutagenesis, July 1, 2003; 18(4): 377 - 385. [Abstract] [Full Text] [PDF]

				X. Wu, H. Zhao, C. I. Amos, S. Shete, N. Makan, W. K. Hong, F. F. Kadlubar, and M. R. Spitz p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity J Natl Cancer Inst, May 1, 2002; 94(9): 681 - 690. [Abstract] [Full Text] [PDF]

				L. M. Pierce, L. Sivaraman, W. Chang, A. Lum, T. Donlon, A. Seifried, L. R. Wilkens, A. F. Lau, and L. Le Marchand Relationships of TP53 Codon 72 and HRAS1 Polymorphisms with Lung Cancer Risk in an Ethnically Diverse Population Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1199 - 1204. [Abstract] [Full Text]

				R. Fan, M.-T. Wu, D. Miller, J. C. Wain, K. T. Kelsey, J. K. Wiencke, and D. C. Christiani The p53 Codon 72 Polymorphism and Lung Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2000; 9(10): 1037 - 1042. [Abstract] [Full Text]

				Y.-C. Wang, C.-Y. Chen, S.-K. Chen, Y.-Y. Chang, and P. Lin p53 Codon 72 Polymorphism in Taiwanese Lung Cancer Patients: Association with Lung Cancer Susceptibility and Prognosis Clin. Cancer Res., January 1, 1999; 5(1): 129 - 134. [Abstract] [Full Text] [PDF]